Clinical Trials
79 trialsDose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
ALPHA3
Allogene Therapeutics
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
ROTATE
Yale University
SHERLOCK
University Health Network, Toronto
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
University of Aarhus
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
PREDICT-RD
UNC Lineberger Comprehensive Cancer Center
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
PALAVY
Abramson Cancer Center at Penn Medicine
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
ctDNA in Cutaneous Squamous Cell Carcinoma
Massachusetts Eye and Ear Infirmary
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Peking University People's Hospital
FLAMINGO-01
Greenwich LifeSciences, Inc.
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University
MiRaDoR
MedSIR
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
University of Oklahoma
GEMINI Breast
Tempus AI
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Peking University People's Hospital
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Peking University People's Hospital
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Columbia University
Caris Biorepository Research Protocol
Caris Science, Inc.
EURHOLY
Assistance Publique - Hôpitaux de Paris
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
S101MRD
Peking University People's Hospital
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
RenJi Hospital
NeckTAR-IN
Centre Jean Perrin
HTLP-ONCO
Assistance Publique - Hôpitaux de Paris
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
GOLD
University of Rochester
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Hadassah Medical Organization
VERDI
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
University Hospital, Montpellier
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
University Hospital, Montpellier
NIP IT!
University Health Network, Toronto
DARA_T_ALL
Tata Memorial Centre
EpLCART
Peter MacCallum Cancer Centre, Australia
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Ruijin Hospital
LumenDx
JaxBio Ltd
BRALLA
Instituto do Cancer do Estado de São Paulo
CR1STAL
Second Xiangya Hospital of Central South University
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Peking University People's Hospital